Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women

Chinese Medical Journal

Volumn 118, Issue 14, 2005, Pages 1167-1174

  Su, Shao Yong ^a   Chen, Jian Hong ^a   Huang, Jian Feng ^a   Wang, Xiao Ling ^a   Zhao, Jian Gong ^a   Shen, Yan ^b   Qiang, Bo Qin ^b   Gu, Dong Feng ^a  

^a FUWAI HOSPITAL   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Chinese Han women; Coronary heart disease; Paraoxonase; Paraoxonase gene cluster

Indexed keywords

ALANINE; ARGININE; ARYLDIALKYLPHOSPHATASE; CYSTEINE; GLUTAMINE; GLYCINE; PHENYLACETIC ACID; SERINE; THREONINE;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENE CLUSTER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PATIENT SELECTION; RANDOMIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CORONARY DISEASE; FEMALE; HAPLOTYPES; HUMANS; MIDDLE AGED; MULTIGENE FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 22944463801     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000;41:1495-1508.
2. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-842.
3. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-253.
4. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-2891.
5. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-287.
6. Primo-Parmo SL, Sorenson RC, Teiber J, et al. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996; 33:498-507.
7. Reddy ST, Wadleigh DJ, Grijalva V, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001;21:542-547.
8. Ng CJ, Wadleigh DJ, Gangopadhyay A, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001;276:44444-44449.
9. Ruiz J, Blanche H, James RW, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995;346:869-872.
10. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99:62-66.
11. Sanghera DK, Aston CE, Saha N, et al. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36-44.
12. Chen Q, Reis SE, Kammerer CM, et al. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women' s Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 2003;72:13-22.
13. Sanghera DK, Saha N, Kamboh MI. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 1998;136: 217-223.
14. Gardemann A, Philipp M, Hess K, et al. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 2000;152:421-431.
15. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:516-521.
16. Suehiro T, Nakamura T, Inoue M, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000;150:295-298.
17. Brophy VH, Hastings MD, Clendenning JB, et al. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001;11:77-84.
18. Leviev I, Righetti A, James RW. Paraoxonase promoter polymorphism T (-107) C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 2001;79:457-463.
19. Wheeler JG, Keavney BD, Watkins H, et al. Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies. Lancet 2004;363:689-695.
20. Malin R, Loimaala A, Nenonen A, et al. Relationship between high-density lipoprotein paraoxonase gene M/L55 polymorphism and carotid atherosclerosis differs in smoking and nonsmoking men. Metabolism 2001;50. 1095-1101.
21. Cobb MM, Teitlebaum H, Risch N, et al. Influence of dietary fat, apolipoprotein E phenotype, and sex on plasma lipoprotein levels. Circulation 1992; 86: 849-857.
22. Thomas JL, Braus PA. Coronary artery disease in women. A historical perspective. Arch Intern Med 1998;158:333-337.
23. Wang X, Fan Z, Huang J, et al. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 2003;23:328-334.
24. Brophy VH, Jampsa RL, Clendenning JB, et al. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001;68:1428-1436.
25. Furlong CE, Costa LG, Hassett C, et al. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem Biol Interact 1993;87:35-48.
26. Zapata C, Carollo C, Rodriguez S. Sampling variance and distribution of the D′ measure of overall gametic disequilibrium between multiallelic loci. Ann Hum Genet 2001;65:395-406.
27. Zhao JH, Curtis D, Sham PC. Model-free analysis and permutation tests for allelic associations. Hum Hered 2000;50:133-139.
28. Wallenstein S, Hodge SE, Weston A. Logistic regression model for analyzing extended haplotype data. Genet Epidemiol 1998;15:173-181.
29. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-989.
30. Furlong CE, Li WF, Costa LG, et al. Genetically determined susceptibility to organophosphorus insecticides and nerve agents: developing a mouse model for the human PON1 polymorphism. Neurotoxicology 1998;19:645-650.
31. James RW, Leviev I, Ruiz J, et al. Promoter polymorphism T (-107) C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 2000;49:1390-1393.